Sometimes I’m amazed at how oblivious
some people in this world can be. Actually, I should say it really
doesn’t amaze me given this is the world of diabetes, which is full
of clueless opinions. I mention this after some conversations on the
nature of the insulin market. Yes, people are beginning to wake up
to the fact (yes, those damn pesky facts again), that insulins have
become a commodity. This is particularly true with long-acting
insulins, of which there are now 5, one being a biosimilar.
Lilly has the biosimilar, Basaglar,which is winning the war that counts: formulary position. Lantus,
the current leader, isn’t just losing the war, it’s losing by a
mile. Starting next year, when formulary changes go into full effect,
Basaglar will become the long-acting insulin of choice. Not because
it’s any better than Lantus — it isn’t. It’s the same as
Lantus, only cheaper — which is exactly the point.
Still, many seem to believe there will
be pushback from physicians. Why would they switch any patient from
Lantus to Basaglar, especially when Lantus works so well? First, as
much as I hate to state the obvious, it really won’t be left up to
the physician. It will be the payor and formulary position that
wins, not the opinion of the physician. Think about the discussion a
physician would have with a Lantus-using patient after these
formulary changes take place.
“Mr./Ms. Patient, you know I would
like to keep you on Lantus. It’s been a great drug that has worked
very well for you. Now I could keep you on Lantus, but there is a
slight problem: your insurance company no longer covers Lantus. You
can stay on Lantus, but I must warn you that it’s going to cost you
where it hurts most: in your wallet. Your alternative is to go on
this new insulin called Basaglar, which is basically the same as
Lantus and is covered by your insurance.
Now I know what you’re thinking:
should you trust this new insulin, is it really the same as Lantus?
Let me assure you that you have nothing to worry about, for two
reasons. First, according to all the studies I have read, Basaglar
works just as well as Lantus. Second, Basaglar is not made by some
no-name company you have never heard of; it’s made by Eli Lilly, a
company with a long and distinguished history in diabetes.
Now I want to say that I am not happy
about the changes made by your insurance company, although I am not
surprised by their decision. So, the choice, as always, is up to
you. You can stay on Lantus and pay more — likely a lot more. Or
you can switch to Basaglar and pay what you were paying before. You
tell me.
This type of discussion is about to
happen in physician offices in 2017; likely sooner, as we’re pretty
sure insurance companies have been informing patients about the
upcoming changes in formulary. Changes which they will support so
that the patient feels comfortable switching from a drug that works
very well to one they have never heard of. In the end, patients will
accept these changes, as at the end of the day this isn’t about
whether Basaglar is as good as Lantus: this is about money. While
there may be some who will pay a premium for Lantus, the majority
will not.